Jessica Hope Roark

Array ( [id] => 14454275 [patent_doc_number] => 10323090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-18 [patent_title] => PD1 and/or LAG3 binders [patent_app_type] => utility [patent_app_number] => 15/353919 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 91 [patent_no_of_words] => 47870 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15353919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471271 [patent_doc_number] => 20170058054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM' [patent_app_type] => utility [patent_app_number] => 15/351275 [patent_app_country] => US [patent_app_date] => 2016-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 26911 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15351275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551923 [patent_doc_number] => 20180327509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/775410 [patent_app_country] => US [patent_app_date] => 2016-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11987803 [patent_doc_number] => 20170291957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS' [patent_app_type] => utility [patent_app_number] => 15/346439 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10641 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979343 [patent_doc_number] => 20170283498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'THERAPEUTIC CD47 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/345691 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14022 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15345691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604113 [patent_doc_number] => 20170121414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses' [patent_app_type] => utility [patent_app_number] => 15/340290 [patent_app_country] => US [patent_app_date] => 2016-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25406 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15340290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590087 [patent_doc_number] => 20180346592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => NOVEL ANTI-GLYPICAN 3 ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 15/771527 [patent_app_country] => US [patent_app_date] => 2016-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11592 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15771527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706287 [patent_doc_number] => 20170174786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/281493 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 54999 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943303 [patent_doc_number] => 20170247454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'ANTI-PD1 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/280810 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 34074 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15280810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448599 [patent_doc_number] => 09982052 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Immunological reagents [patent_app_type] => utility [patent_app_number] => 15/272707 [patent_app_country] => US [patent_app_date] => 2016-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 59 [patent_no_of_words] => 22672 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15272707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14005623 [patent_doc_number] => 10221249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => Method of making patient specific anti-idiotype antibodies [patent_app_type] => utility [patent_app_number] => 15/261084 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 38725 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 267 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15261084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11492638 [patent_doc_number] => 20170066823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING MOLECULES AND METHODS OF USING THE MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/258683 [patent_app_country] => US [patent_app_date] => 2016-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 51890 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13761269 [patent_doc_number] => 10172963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Method of binding a CSE1L tumor marker in a tumor of an animal [patent_app_type] => utility [patent_app_number] => 15/257669 [patent_app_country] => US [patent_app_date] => 2016-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13749 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15257669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12305940 [patent_doc_number] => 09938346 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies [patent_app_type] => utility [patent_app_number] => 15/248562 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 139 [patent_figures_cnt] => 190 [patent_no_of_words] => 68477 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371985 [patent_doc_number] => 20180237533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => CHIMERIC ANTIGEN RECEPTORS WITH INTEGRATED CONTROLLABLE FUNCTIONS [patent_app_type] => utility [patent_app_number] => 15/752195 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15752195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756611 [patent_doc_number] => 10975148 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed [patent_app_type] => utility [patent_app_number] => 15/750453 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 7812 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14171725 [patent_doc_number] => 10259858 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Insertable variable fragments of antibodies and modified a1-a2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors [patent_app_type] => utility [patent_app_number] => 15/228718 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 15472 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342899 [patent_doc_number] => 20180222989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => COMBINATION TREATMENTS AND USES AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 15/749355 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15749355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311473 [patent_doc_number] => 20180207273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 [patent_app_type] => utility [patent_app_number] => 15/747326 [patent_app_country] => US [patent_app_date] => 2016-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105059 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 494 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15747326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13035425 [patent_doc_number] => 10039825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-07 [patent_title] => Combination therapy with CD4 lymphocyte depletion and MTOR inhibitors [patent_app_type] => utility [patent_app_number] => 15/218464 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 7812 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15218464 [rel_patent_id] =>[rel_patent_doc_number] =>)